Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection

Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administration-approved therapies for mCRPC with demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Den, Robert B., George, Daniel, Pieczonka, Christopher, McNamara, Megan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445613/
https://www.ncbi.nlm.nih.gov/pubmed/30844849
http://dx.doi.org/10.1097/COC.0000000000000528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445613/
https://www.ncbi.nlm.nih.gov/pubmed/30844849
http://dx.doi.org/10.1097/COC.0000000000000528

Ejemplares similares